

AAPS Connection

American Association of Pharmaceutical Scientists

March 2011

Celebrate with AAPS in 2011!

AAPS will celebrate its 25th anniversary in 2011! AAPS has spent the past 25 years offering timely educational programming and professional development opportunities to pharmaceutical scientists. AAPS will commemorate its 25th year by recognizing the ways the organization has developed science and impacted health. Upcoming issues of the *AAPS Newsmagazine* will include articles featuring profiles of AAPS founders, past presidents, and members from diverse disciplines. AAPS will also highlight significant events in the pharmaceutical sciences and AAPS's impact in the field during the past 25 years. Plus, AAPS will look ahead to what the future may have in store for the pharmaceutical sciences. There will be other exciting events throughout the year, all culminating at the AAPS 25th Anniversary Celebration at the 2011 AAPS Annual Meeting and Exposition in Washington, DC.



Emerging Oral Delivery Strategies and Technologies to Enable Biopharmaceutical Performance of BCS II, III and IV Molecules

April 14–15, 2011

Sheraton Inner Harbor, Baltimore, MD, USA

Goals and Objectives

For small molecules, approximately 60–70% of NMEs are BCS II and IV, and there is increasing need for drug delivery technologies to enable the development of “drug-like” molecules in a timely and cost-effective manner. Proper biopharmaceutical and ADMET properties along with adequate selectivity and potency minimize subsequent failure risks and increase the chance that the most promising leads are advanced to development candidates. In the case of macromolecules (BCS III), intestinal permeability and metabolism are still the major barriers to overcome, with no commercial product on the market despite significant advancements over the last two decades. Proper selection and evaluation of a suitable drug delivery technology using proper *in vitro/in vivo* methodologies by considering the physicochemical and biopharmaceutical properties of the molecule/macromolecule are critical to the overall drug discovery and development strategy and success. This feature will be highlighted throughout the workshop and introduced by two keynote talks on new paradigms in drug discovery and development and emerging drug delivery technologies. The following three areas will then be covered, one on general drug development principles and considerations and two on specific drug delivery technologies and case studies: physicochemical and biopharmaceutical properties and evaluation tools, lipid-based systems and solid dispersions, and prodrugs and nanoparticles.

AAPS Launches New LinkedIn Subgroup!



AAPS has launched a new LinkedIn Subgroup, AAPS Careers, to focus discussion on careers in the pharmaceutical sciences within the AAPS LinkedIn community. The new site will also support the AAPS Online Career Center.

While the AAPS Online Career Center remains the most comprehensive resource for hiring companies who wish to recruit highly qualified candidates in the pharmaceutical sciences community, the new LinkedIn Subgroup, AAPS Careers, will help streamline communication with members and make it easier for them to

- ▶ share knowledge on recent hiring practices,
- ▶ learn through experiences from their peers, and
- ▶ find crucial information on the current job market.

Please join the new LinkedIn Subgroup, AAPS Careers, today!

For more information, please visit www.aapspharmaceutica.com/oraldelivery.

AAPS Workshop on Delivery and Disposition of Biotherapeutics Across the Blood-Brain Barrier

May 14–15, 2011

Hilton San Francisco Union Square
San Francisco, CA, USA

Goals and Objectives

In recent years, a significant effort has been guided toward the identification of novel therapeutic targets for central nervous system (CNS) disorders. However, these efforts have not translated into robust success in developing biotherapeutic modalities for CNS diseases in the industry drug development pipeline. The primary reason is that the blood-brain barrier (BBB) isolates and protects CNS structures, creating a unique biochemically and immunologically privileged environment. Therefore, passage of macromolecules across this barrier is fraught with challenges. Further, even if 0.1 to 0.2% of any biotherapeutic drug modality crosses the BBB, there is no consensus in terms of method to be used or tissue/fluids to be collected for the optimum measurements of the therapeutic. In recent years, some technologies have evolved from academia or the small biotech industry that promise to deliver biotherapeutics in sufficient quantities. Although successful at the preclinical stage in lower vertebrates, none of these technologies have emerged in the clinical setting. What could be the issues stifling this progress? Investigators in academia as well as in industry have realized that there is a definite lack of proper communication channel that has prevented progress in the development of introduction of biotherapeutics across the BBB. Can we fix this?

For more information, please visit
www.aapspharmaceutica.com/Biotherapeutics.

2011 AAPS National Biotechnology Conference

May 16–18, 2011

Hilton San Francisco, Union Square
San Francisco, CA, USA



The 2011 AAPS National Biotechnology Conference will be taking place May 16–19, 2011 at the Hilton San Francisco Union Square in San Francisco, California. Attendees will have access to one full week of educational programming during this annual event devoted to advancing health through innovations in biotherapeutics.

The week begins with the AAPS workshop, Delivery and Disposition of Biotherapeutics Across the Blood-Brain Barrier, taking place May 14–15. The two-day 2011 AAPS Immunogenicity Training Course, Development of Ligand Binding Analytical Methods to Support Immunogenicity

AAPS Connection
2107 Wilson Blvd., Suite 700, Arlington, VA 22201-3042 USA, Ph: +1 703 243-2800

Testing Theoretical to Practical Considerations, will also take place May 14–15.

The week proceeds through the full 2011 AAPS National Biotechnology Conference programming. The 2011 programming consists of a Plenary Session, Symposia, Roundtables, Posters, and Hot Topics. The week concludes with three short courses. Additionally, an Exposition Hall will be hosting major companies.

If you have any questions about the program or registration procedures, please contact the AAPS office by calling 703-243-2800 or emailing meetings@aaps.org. The 2011 AAPS National Biotechnology Conference is designed to provide a complete educational event allowing each and every attendee the ability to customize their experience with the goal of advancing health through innovations in biotherapeutics.

AAPS eLearning

Check out our upcoming and archived webinars!

www.aapspharmaceutica.com/webinars



Upcoming AAPS Meetings

Log onto www.aapspharmaceutica.com/meetings for details.

► April 14-15, 2011

AAPS Workshop on Emerging Oral Delivery Strategies and Technologies to Enable Biopharmaceutical Performance of BCS II, III and IV Molecules
Sheraton Inner Harbor Hotel, Baltimore, MD, USA

► May 14-15, 2011

AAPS Workshop on Delivery and Disposition of Biotherapeutics Across the Blood-Brain Barrier
Hilton San Francisco Union Square, San Francisco, CA, USA

► May 16-18, 2011

2011 AAPS National Biotechnology Conference
Hilton San Francisco Union Square, San Francisco, CA, USA

► October 22-23, 2011

AAPS Workshop on Facilitating Oral Product Development and Reducing Regulatory Burden through Novel Approaches to Assess Bioavailability/Bioequivalence
Walter E. Washington Convention Center
Washington, D.C., USA

► October 23-27, 2011

2011 AAPS Annual Meeting and Exposition
Walter E. Washington Convention Center
Washington, D.C., USA



March 2011